Holen Sie sich die Stockscreener-App
20.09
2.33%
-0.48
Assembly Biosciences Inc Aktie (ASMB) Neueste Nachrichten
Assembly Biosciences to present ABI-6250 phase 1a data at AASLD By Investing.com - Investing.com South Africa
Assembly Biosciences, Inc. Presents Positive Phase 1a Safety, Tolerability And Target Engagement Data For ABI-6250 At AASLD The Liver Meeting - www.marketscreener.com
Assembly Biosciences Plans to Present Posters Featuring New Phase 1a Data From ABI-6250 Program - Yahoo Finance
Assembly Biosciences to present ABI-6250 phase 1a data at AASLD - Investing.com
Assembly Biosciences, Inc. (ASMB) stock price, news, quote and history - Yahoo Finance Australia
Assembly Biosciences Announces Two Phase 1a ABI-6250 Posters to Be Presented at The Liver Meeting 2026 - Quiver Quantitative
Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026 - The Manila Times
EBITDA per share of Assembly Biosciences, Inc. – HAN:V7B - TradingView
Diluted net income available to common stockholders of Assembly Biosciences, Inc. – HAN:V7B - TradingView
Equity in earnings of Assembly Biosciences, Inc. – HAN:V7B - TradingView
Assembly Biosciences, Inc. Actuals & Estimates (HAN:V7B) - TradingView
V7B Forecast — Price Target — Prediction for 2027 - TradingView
Assembly Biosciences (Nasdaq:ASMB)Stock Analysis - Simply Wall Street
Assembly Biosciences, Inc.(NasdaqGS:ASMB) added to S&P Biotechnology Select Industry Index - marketscreener.com
Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference - The Manila Times
Assembly Bio schedules a live webcast for Sept. 16 - Stock Titan
Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks - TradingView
Why is Assembly Biosciences stock surging today? By Investing.com - Investing.com Australia
Assembly Bio opts into 40% U.S. profit share for herpes drug By Investing.com - Investing.com South Africa
Why is Assembly Biosciences stock surging today? - Investing.com
Why is Assembly Biosciences stock surging today? By Investing.com - Investing.com Canada
Assembly Biosciences (ASMB) Shares U.S. Development Costs and Profits with Gilead on Herpes Treatment - GuruFocus
Assembly Bio stock gains after exercising Gilead profit option By Investing.com - Investing.com South Africa
Assembly Bio stock gains after exercising Gilead profit option By Investing.com - Investing.com Nigeria
Assembly Bio stock gains after exercising Gilead profit option By Investing.com - Investing.com India
Assembly Bio stock gains after exercising Gilead profit option By Investing.com - Investing.com Canada
Assembly Bio stock gains after exercising Gilead profit option - investing.com
Assembly Bio stock gains after exercising Gilead profit option By Investing.com - Investing.com UK
Assembly Bio stock gains after exercising Gilead profit option - Investing.com
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program - The Manila Times
Assembly Bio opts into 40% U.S. profit share for herpes drug - Investing.com Canada
Assembly Bio opts into 40% U.S. profit share for herpes drug By Investing.com - Investing.com India
Assembly Biosciences exercises profit share option with Gilead for HSV program - TipRanks
Assembly Bio opts into 40% U.S. profit share for herpes drug - Investing.com UK
A $75 million Gilead payment is due in Q4, while Assembly Bio expects cash to fund operations into 2029. - Stock Titan
Zacks.com featured highlights include EuroDry, RCM, Assembly Biosciences, Delcath and National Energy Services - Yahoo Finance
Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High? - Yahoo Finance
Should You Buy Assembly Biosciences (ASMB) After Golden Cross? - Yahoo Finance
How Assembly Biosciences Inc. (ASMB) Affects Rotational Strategy Timing - Stock Traders Daily
Here's Why Momentum in Assembly Biosciences (ASMB) Should Keep going - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM) and Assembly Biosciences (ASMB) - The Globe and Mail
ASMB Maintained by Mizuho -- Price Target Lowered to $45 - GuruFocus
ASMB Initiates Coverage On UBS -- Price Target Announced at $52. - GuruFocus
Assembly Biosciences Price Target Announced at $52.00/Share by UBS - Moomoo
Assembly Biosciences price target raised to $53 from $45 at Mizuho - TipRanks
UBS initiates Assembly Biosciences stock with buy rating on antiviral platform - Investing.com Nigeria
UBS initiates Assembly Biosciences stock with buy rating on antiviral platform - Investing.com
UBS initiates Assembly Biosciences stock with buy rating on antiviral platform By Investing.com - Investing.com South Africa
UBS initiates Assembly Biosciences stock with buy rating on antiviral platform - Investing.com UK
Mizuho lowers Assembly Biosciences stock price target to $45 - Investing.com
4.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):